NEXTBio Capital Management LP Purchases New Shares in Structure Therapeutics Inc. Sponsored ADR $GPCR

NEXTBio Capital Management LP purchased a new stake in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 94,443 shares of the company’s stock, valued at approximately $6,569,000. Structure Therapeutics accounts for approximately 3.9% of NEXTBio Capital Management LP’s investment portfolio, making the stock its 10th biggest position. NEXTBio Capital Management LP owned about 0.16% of Structure Therapeutics at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Aberdeen Group plc boosted its stake in Structure Therapeutics by 46.1% in the 3rd quarter. Aberdeen Group plc now owns 586,869 shares of the company’s stock valued at $16,432,000 after purchasing an additional 185,245 shares during the period. Jefferies Financial Group Inc. bought a new stake in Structure Therapeutics in the 3rd quarter valued at $4,770,000. Private Capital Advisors Inc. bought a new stake in Structure Therapeutics in the 3rd quarter valued at $1,545,000. Capricorn Fund Managers Ltd bought a new stake in Structure Therapeutics in the 4th quarter valued at $17,568,000. Finally, First Light Asset Management LLC boosted its stake in Structure Therapeutics by 61.5% in the 3rd quarter. First Light Asset Management LLC now owns 197,350 shares of the company’s stock valued at $5,526,000 after purchasing an additional 75,124 shares during the period. 91.78% of the stock is currently owned by institutional investors.

Structure Therapeutics Stock Performance

GPCR opened at $42.93 on Friday. The firm has a market cap of $3.05 billion, a P/E ratio of -49.34 and a beta of -1.35. Structure Therapeutics Inc. Sponsored ADR has a 52-week low of $15.80 and a 52-week high of $94.90. The business’s fifty day moving average is $43.64 and its 200-day moving average is $57.18.

Structure Therapeutics (NASDAQ:GPCR) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.35) earnings per share for the quarter, topping the consensus estimate of ($0.39) by $0.04. On average, research analysts predict that Structure Therapeutics Inc. Sponsored ADR will post -1.64 earnings per share for the current fiscal year.

Analysts Set New Price Targets

GPCR has been the subject of several recent research reports. Leerink Partners restated an “outperform” rating on shares of Structure Therapeutics in a research note on Monday, March 16th. BMO Capital Markets set a $145.00 target price on Structure Therapeutics and gave the stock an “outperform” rating in a report on Tuesday, March 17th. Wolfe Research began coverage on Structure Therapeutics in a report on Thursday, March 26th. They set a “peer perform” rating on the stock. HC Wainwright reduced their target price on Structure Therapeutics from $100.00 to $70.00 and set a “buy” rating on the stock in a report on Thursday. Finally, Canaccord Genuity Group began coverage on Structure Therapeutics in a report on Monday, April 27th. They set a “buy” rating and a $101.00 target price on the stock. Three research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $106.75.

About Structure Therapeutics

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.